Document:

Exhibit 10.12

FORM OF

LETTER OF CREDIT COLLATERALIZATION AGREEMENT

 

This Letter of Credit
Collateralization Agreement (this “Agreement”) is made effective as of March 22, 2019 (the “Effective
Date”), by and among Dougherty’s Pharmacy, Inc. (the “Company”) and the parties listed on Schedule
1 (each a “Collateral Party” and collectively, the “Collateral Parties”). The
Company and the Collateral Parties are collectively referred to herein as the “Parties.”

 

WHEREAS, the Company
has requested that LegacyTexas Bank (“Legacy”) establish that certain Irrevocable Letter of Credit No. 444801
(the “Letter of Credit”) in the initial amount of $825,000 effective as of the Effective Date and initially
expiring on March 22, 2020 (subject to adjustment pursuant to the terms of the Letter of Credit) in favor of Associated Food Stores,
Inc.;

 

WHEREAS, in connection
with the issuance of the Letter of Credit, Legacy required the Company to execute a Promissory Note on the Effective Date (the
“Promissory Note”) providing a line of credit in the principal amount of up to $825,000 which is secured by
certain deposit accounts (each a “Deposit Account, and collectively, the “Deposit Accounts”) owned
by the Collateral Parties in the amounts set forth on Schedule 1, collectively holding an amount $825,000 (the “Collateral”);

 

WHEREAS, the interest
in the Collateral is granted pursuant to Assignments of Deposit Accounts in favor of Legacy effective as of the Effective Date
(each an “Assignment,” and collectively, the “Assignments”) executed by the Collateral Parties;

 

WHEREAS, the Collateral
Parties have agreed to provide and maintain such Assignments in the Collateral under the terms of this Agreement and in exchange
for the consideration provided for herein;

 

NOW THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and subject to the terms and conditions
set forth below, the Parties hereto, intending to be legally bound, hereby agree as follows:

 

1.       Assignment
of Collateral. Each of the Collateral Parties hereby agrees to execute and maintain their respective Assignments in favor
of Legacy to secure the Promissory Note pursuant to the terms thereof;

 

Quarterly Maintenance
Payments. As partial consideration for executing and maintaining the Assignments of Collateral, the Company shall pay each
Collateral Party an amount equal to 10% per annum on the amount held in the Deposit Account assigned as Collateral pursuant to
such Collateral Party’s Assignment, accruing on the basis of a year of 365 days for the actual number of days elapsed (“Maintenance
Payments”) until the earlier of such time as (a) such Assignment is terminated or expires pursuant to its terms or (b)
the Collateral Party is reimbursed for such Collateral as provided herein. Maintenance Payments shall be due and payable quarterly
on each March 31, June 30, September 30 and December 31 at the address specified on Schedule 1 hereto. The first such Maintenance
Payment shall be due on June 30, 2019. In the event that the Company shall fail to pay any Maintenance Payment or reimbursement
payment provided for in Section 4 hereof when due and such payment shall not have been made within five (5) days of the
Company’s receipt of a Collateral Party’s written notice of such failure, until such time as such delinquent payment(s)
are made, Maintenance payments shall increase to the lesser of 18% per annum on the amount held in the Deposit Account assigned
as Collateral pursuant to such Collateral Party’s Assignment or the Highest Lawful Rate. “Highest Lawful Rate”
means the maximum nonusurious interest rate, if any, that at any time or from time to time may be contracted for, taken, reserved,
charged, or received on the indebtedness under the laws of the United States and the State of Texas applicable thereto which are
presently in effect or, to the extent allowed by law, under such applicable laws of the United States and the State of Texas which
may hereafter be in effect and which allow a higher maximum nonusurious interest rate than applicable laws now allow, in any case
after taking into account, to the extent required by applicable law, any and all relevant payments or charges under any documents
executed in connection herewith.

 

2.               
Issuance of Warrants. As additional consideration for executing and maintaining the Assignments of Collateral, the
Company shall issue to each Collateral Party a warrant in the form attached hereto as Exhibit A (each, a “Warrant”
and, collectively, the “Warrants”) to purchase up to a number of shares of Common Stock, par value $0.0001
of the Company (the “Warrant Shares”), equal to the number of shares set forth opposite each Collateral Party’s
name on Schedule 1 hereto;

 

 

 

    	 	1	 

     

    

 

3.               
Reimbursement of Collateral Parties. In the event that Legacy applies any funds representing Collateral of any Collateral
Party to obligations of the Company for indebtedness under the Promissory Note or any other obligation of the Company under the
terms of one or more of the Assignments, the Company shall promptly (but in any event within 30 days of application of such amounts)
reimburse any amounts so applied by Legacy. In the event that the

 

4.               
Further Assurances. The Parties hereto hereby agree to enter into and execute and deliver such further instruments
and documents, including assignments and conveyance documents, security agreements and commitments, and similar contracts and agreements,
and take such other reasonable actions as may be necessary or appropriate to implement and effectuate the terms, provisions and
actions described in this Agreement, as reasonably determined and requested by the Company.

 

5.               
Representations and Warranties of the Company. The Company represents and warrants to each Collateral Party that,
as of the Effective Date:

 

(a)             
Organization and Good Standing. The Company (i) is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware; (ii) has the power and authority to own, lease and operate its properties and carry on
its business as now conducted; and (iii) is duly qualified, licensed to do business and in good standing as a foreign corporation
in each jurisdiction where the failure to be so qualified or licensed could reasonably be expected to have a material adverse effect
on the Company.

 

(b)            
Valid Issuance of Warrant Shares.

 

(i)              
The Warrant Shares. The Warrant Shares issuable upon exercise of the Warrants will, when issued, sold and delivered
in accordance with the terms of this Agreement and the Warrant for the consideration provided for herein and therein, be duly authorized
and validly issued.

 

(ii)            
Reserve. The Company has reserved and will hold available out of the aggregate of its authorized but unissued common
stock the number of shares of its common stock issuable upon the exercise of the Warrants, until such time as the Warrants are
exercised, terminated or expire.

 

(iii)          
Securities Laws. Based in part on the representations made by the Collateral Parties in Section 7 hereof, the offer
and sale of the Warrants solely to the Collateral Parties in accordance with this Agreement and the Warrant and (assuming no change
in currently applicable law, no transfer of Warrants by the Collateral Party and no commission or other remuneration is paid or
given, directly or indirectly, for soliciting the issuance of Warrant Shares upon exercise of the Warrants) the issuance of the
Warrant Shares is intended to be exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities
Act”) and the securities registration and qualification requirements of the currently effective provisions of the securities
laws of the states in which each Collateral Party is a resident based upon their addresses set forth on Schedule 1 attached
hereto.

 

(c)             
Authority. The execution, delivery and performance by the Company of each of this Agreement and the Warrants to be
executed by the Company and the consummation of the transactions contemplated thereby (i) are within the power of the Company and
(ii) have been duly authorized by all necessary actions on the part of the Company.

 

(d)            
Enforceability. Each of this Agreement and the Warrants executed, or to be executed, by the Company has been, or
will be, duly executed and delivered by the Company and constitutes, or will constitute, a legal, valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other
laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles
of equity.

 

 

 

    	 	2	 

     

    

 

(e)             
Non-Contravention. The execution and delivery by the Company of the this Agreement and the Warrants executed by the
Company and the performance and consummation of the transactions contemplated thereby do not and will not (i) violate the Company’s
certificate of incorporation or bylaws or any material judgment, order, writ, decree, statute, rule or regulation applicable to
the Company; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate
(whether after the giving of notice or lapse of time or both), any material mortgage, indenture, agreement, instrument or contract
to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any security interest,
mortgage, pledge, lien, claim, charge or other encumbrance (“Lien”) upon any property, asset or revenue of the Company
(other than any Lien arising under this Agreement and the Warrants) or the suspension, revocation, impairment, forfeiture, or nonrenewal
of any material permit, license, authorization or approval applicable to the Company, its business or operations, or any of its
assets or properties.

 

(f)             
Approvals. No consent, approval, order or authorization of, or registration, declaration or filing with, any governmental
authority or other Person (including, without limitation, the shareholders of any Person) is required in connection with the execution
and delivery of this Agreement and the Warrants executed by the Company and the performance and consummation of the transactions
contemplated thereby, other than such as have been obtained and remain in full force and effect and other than such qualifications
or filings under applicable securities laws as may be required in connection with the transactions contemplated by this Agreement.

 

(g)            
No Other Representations. The Company has not made, nor will be deemed to have made, any representation or warranty
in connection with this Agreement, the Warrants or the transactions contemplated hereby other than as expressly made in this Section
6.

 

6.       Representations
and Warranties of Collateral Parties. Each Collateral Party, severally and not jointly, represents and warrants to the Company
that, as of the Effective Date:

 

(a)       Binding
Obligation. Such Collateral Party has full legal capacity, power and authority to execute and deliver this Agreement and
to perform its obligations hereunder. This Agreement and the Warrant issued to such Collateral Party constitute valid and
binding bligations of such Collateral Party, enforceable in accordance with their terms, except as limited by bankruptcy,
insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally
and general principles of equity.

 

(b)          
Securities Law Compliance. Such Collateral Party has been advised that the Warrants and the underlying Warrant Shares
have not been registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are
registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements
is available. Such Collateral Party is aware that the Company is under no obligation to effect any such registration with respect
to the Warrants or the underlying Warrant Shares or to file for or comply with any exemption from registration. Such Collateral
Party has not been formed solely for the purpose of making this investment and is acquiring the Warrants hereunder for its own
account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof,
and Collateral Party has no present intention of selling, granting any participation in, or otherwise distributing the same. Such
Collateral Party has such knowledge and experience in financial and business matters that such Collateral Party is capable of evaluating
the merits and risks of such investment, is able to incur a complete loss of such investment without impairing such Collateral
Party’s financial condition and is able to bear the economic risk of such investment for an indefinite period of time. Such
Collateral Party is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act and shall
submit to the Company such further assurances of such status as may be reasonably requested by the Company. The residency of the
Collateral Party (or, in the case of a partnership or corporation, such entity’s principal place of business) is correctly
set forth beneath such Collateral Party’s name on Schedule 1 hereto.

 

(c)           
Access to Information. Such Collateral Party acknowledges that the Company has given such Collateral Party access
to the corporate records and accounts of the Company and to all information in its possession relating to the Company, has made
its officers and representatives available for interview by such Collateral Party, and has furnished such Collateral Party with
all documents and other information required for such Collateral Party to make an informed decision with respect to the acquisition
of the Warrants.

 

 

 

    	 	3	 

     

    

 

(d)          
Tax Advisors. Such Collateral Party has reviewed with its own tax advisors
the U.S. federal, state and local and non-U.S. tax consequences of the transactions contemplated by this Agreement. With respect
to such matters, such Collateral Party relies solely on any such advisors and not on any statements or representations of the Company
or any of its agents, written or oral. Such Collateral Party understands that it (and not the Company) shall be responsible for
its own tax liability that may arise as a result of this investment and the transactions contemplated by this Agreement.

 

7.       Miscellaneous.

 

(a)       Waivers
and Amendments. Any provision of this Agreement and the Warrants may be amended, waived or modified only upon the written consent
of the Company and Collateral Parties granting Assignments covering more than 50% of the aggregate Collateral; provided, however,
that no such amendment, waiver or consent shall: (i) reduce the amount of Collateral specified in an Assignment without the affected
’s written consent, or (ii) reduce the rate of interest of any Note without the affected Collateral Party’s written
consent. Any amendment or waiver effected in accordance with this paragraph shall be binding upon all of the parties hereto.

 

(b)            
Governing Law. This Agreement and all actions arising out of or in connection with this Agreement shall be governed
by and construed in accordance with the laws of the State of Texas, without regard to the conflicts of law provisions of the State
of Texas or of any other state.

 

(c)            
Jurisdiction and Venue. Each of the Parties irrevocably consents to the exclusive
jurisdiction of, and venue in, the state and federal courts in Dallas County in the State of Texas, in connection with any matter
based upon or arising out of this Agreement or the matters contemplated herein, and agrees that process may be served upon them
in any manner authorized by the laws of the State of Texas for such persons.

 

(d)            
Successors and Assigns. Subject to the restrictions on transfer described herein or in the Warrants, the rights and
obligations of the Company and the Collateral Parties shall be binding upon and benefit their respective successors, assigns, heirs,
administrators and transferees of the parties.

 

(e)            
Assignment by the Company. The rights, interests or obligations hereunder may not be assigned, by operation of law
or otherwise, in whole or in part, by the Company without the prior written consent of Collateral Parties granting Assignments
covering more than 50% of the aggregate Collateral.

 

(f)             
Entire Agreement. This Agreement together with the Warrants constitute and contain the entire agreement among the
Company and Collateral Parties with respect to the subject matter hereof and supersede any and all prior agreements, negotiations,
correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof.

 

(g)            
Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed
by registered or certified mail, postage prepaid, sent by electronic mail (if to a Collateral Party or any other holder of Company
securities) or otherwise delivered by hand, messenger or courier service addressed:

 

(i)              
if to a Collateral Party, to the Collateral Party’s address or electronic mail address as shown in Schedule 1,
as may be updated in accordance with the provisions hereof; and

 

(ii)            
if to the Company, to the attention of Stewart Edington at 5924 Royal Lane, Suite 250, Dallas, Texas 75230, or at such other
current address as the Company shall have furnished to the Collateral Parties.

 

Each such notice or other communication
shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier
service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day
delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days
after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and
mailed as aforesaid, or (iii) if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic
mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient,
then on the recipient’s next business day. In the event of any conflict between the Company’s books and records and
this Agreement or any notice delivered hereunder, the Company’s Schedule 1 will control absent fraud or error.

 

 

 

    	 	4	 

     

    

 

(h)            
Severability. The Company’s agreement with each of the Collateral Parties is a separate agreement and the issuance
of the Warrants to each of the Collateral Parties is a separate issuance. Unless otherwise expressly provided herein, the rights
of each Collateral Party hereunder are several rights, not rights jointly held with any of the other Collateral Parties. Any invalidity,
illegality or limitation on the enforceability of the Agreement or any part thereof, by any Collateral Party whether arising by
reason of the law of the respective Collateral Party’s domicile or otherwise, shall in no way affect or impair the validity,
legality or enforceability of this Agreement with respect to other Collateral Parties. If any provision of this Agreement shall
be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions
shall not in any way be affected or impaired thereby.

 

(i)              
Counterparts. CounterpartsThis Agreement may be executed in any number of counterparts, each of which will be
deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the
same agreement. This Agreement and any signed agreement entered into in connection herewith or contemplated hereby, and any amendments
hereto or thereto, to the extent signed and delivered by facsimile, by electronic mail in “portable document format”
(“.pdf”) form, or any other electronic transmission, shall be treated in all manner and respects as an original contract
and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person.
At the request of any party hereto or to any such contract, each other party hereto or thereto shall re-execute original forms
thereof and deliver them to all other parties.

 

[Signatures on following pages]

 

 

 

    	 	5	 

     

    

 

 

IN WITNESS WHEREOF, this Agreement is executed effective as of the Effective Date.

 

	 	COMPANY:
	 	 
	 	DOUGHERTY’S PHARMARCY, INC.,
	 	a Delaware corporation
	 	 
	 	By: _________________________
	 	Name: Setwart Edington
	 	Title: Chief Executive Officer
	 	 
	 	 
	 	COLLATERAL PARTIES:
	 	 
	 	By: _____________________
	 	Name: ___________________
	 	Title: ____________________
	 	 
	 	By: _____________________
	 	Name: ___________________
	 	Title: ____________________
	 	 
	 	By: _____________________
	 	Name: ___________________
	 	Title: ____________________
	 	 
	 	By: _____________________
	 	Name: ___________________
	 	Title: ____________________
	 	 

 

 

 

    	 	6Exhibit 4.33

 

Form of Warrant

 

THIS WARRANT HAS NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH
THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH
ACT AND APPLICABLE LAWS IS AVAILABLE WITH RESPECT THERETO.

 

	No. 00__	March 22, 2019

 

DOUGHERTY’S PHARMACY, INC. 

Warrant for the Purchase of Common Stock

 

FOR VALUE RECEIVED,
DOUGHERTY’S PHARMACY, INC., a Delaware corporation (the “Company”), hereby certifies that [                 ],
or [his/its] permitted transferees or assigns (the “Holder”), is entitled, subject to the provisions
of this Warrant (this “Warrant”), to purchase from the Company, at any time during the Exercise Period (defined
below), [                   ]
([                  ]) shares of
Common Stock (“Common Stock”) as set forth in the Certificate of Incorporation of the Company (the “Certificate
of Incorporation”), subject to adjustment from time to time as hereinafter set forth, at a purchase price equal to $0.20
per share, subject to adjustment from time to time as hereinafter set forth (as may be so adjusted, the “Exercise Price”).
This Warrant has been granted pursuant to the terms of that certain Letter of Credit Collateralization Agreement dated effective
as of March 22, 2019, by and between the Company and the Collateral Parties thereunder (the “Agreement”). Capitalized
terms used but not defined herein shall have the meanings given such terms as set forth in the Agreement.

 

1.       Exercise
of Warrant.

 

(a)       This
Warrant shall be exercisable for a period beginning on the date first set forth above (the “Issuance Date”)
and ending March 22, 2022 (the “Exercise Period”). This Warrant may be exercised in whole or in part during
the Exercise Period by presentation and surrender hereof to the Company at its principal office, with the Purchase Form annexed
hereto (the “Purchase Form”) duly executed and accompanied by proper payment in cash or check in an amount equal
to the aggregate Exercise Price of this Warrant, as specified in such form.

 

(b)       Upon
receipt by the Company of this Warrant and the Purchase Form, together with the aggregate Exercise Price, at such office, in proper
form for exercise, the Holder shall be deemed to be the holder of record of the Common Stock specified in the Purchase Form (the
“Warrant Shares”), notwithstanding that the transfer books of the Company shall then be closed or that certificates
(if any) representing the Warrant Shares shall not then be actually delivered to the Holder. The Company shall pay any and all
documentary, stamp, or similar issue taxes payable in respect of the issuance of the Warrant Shares. The Company shall not, however,
be required to pay any tax that may be payable in respect of any transfer involved in the issuance or delivery of certificates
(if any) representing Warrants or the Warrant Shares in a name other than that of the Holder at the time of surrender for exercise,
and, until the payment of such tax, shall not be required to issue such Warrant Shares. In the event of a partial exercise of
this Warrant, the Company shall execute and deliver a warrant to Holder for the remaining unexercised portion of this Warrant.

 

2.       Transfer,
Assignment, or Loss of Warrant. The Holder of this Warrant shall be entitled to transfer or assign its interest in this Warrant
subject only to the applicable securities laws. Upon such assignment and surrender of this Warrant to the Company, the Company
shall, without charge, execute and deliver a new Warrant in the name of the assignee named in such instrument of assignment and
this Warrant shall promptly be cancelled. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft,
destruction, or mutilation of this Warrant (which may be an affidavit of the Holder in the case of loss, theft, destruction), and
(in the case of loss, theft, or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of
this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like term and date.

 

 

 

    	 	1	 

     

    

 

3.       Reclassification,
Reorganization, Conversion, Consolidation, or Merger. In the case of any Reorganization Transaction (defined below), the Company
shall, as a condition precedent to such transaction, cause effective provisions to be made so that the Holder shall have the right
thereafter, by exercising this Warrant, to purchase the kind and amount of securities and property receivable upon such Reorganization
Transaction by a holder of the number of shares of Common Stock that would have been received upon exercise in full of this Warrant
immediately prior to such Reorganization Transaction. Any such provision shall (a) be binding upon the Holder without the Holder’s
further consent and (b) include provision for adjustments in respect of such securities and property that shall be as nearly equivalent
as may be practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section 3 shall
similarly apply to successive Reorganization Transactions. For purposes of this Section 3, “Reorganization Transaction”
means any reclassification, conversion, or any consolidation or merger of the Company with or into another Person or any sale,
lease, transfer, or conveyance to another Person of the property and assets of the Company as an entirety.

 

4.       Rights.
This Warrant shall not entitle the Holder to any of the rights of a holder of Common Stock until this Warrant is exercised in the
manner provided herein.

 

5.       Securities
Laws. The Holder of this Warrant, by acceptance hereof, acknowledges that this Warrant and the Warrant Shares to be issued
upon exercise hereof are being acquired solely for the Holder’s own account for investment, and that the Holder will not
offer, sell, or otherwise dispose of this Warrant or the Warrant Shares to be issued upon exercise hereof except under circumstances
that will not result in a violation of any federal or state securities laws. Upon exercise of this Warrant, the Holder shall, if
requested by the Company, confirm in writing, in a form reasonably satisfactory to the Company, that the Warrant Shares so purchased
are being acquired for investment, and not with a view toward distribution or resale in violation of applicable securities laws.
Certificates (if any) representing Warrant Shares issued upon exercise hereof shall be stamped or imprinted with a legend in substantially
the form set forth at the heading of this Warrant.

 

6.       Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged, or terminated only in accordance with the Purchase Agreement.
This Warrant and all actions arising out of or in connection with this Warrant shall be governed by and construed in accordance
with the laws of the State of Texas, without regard to the conflicts of law provisions of the State of Texas or of any other state.
Each of the parties irrevocably consents to the exclusive jurisdiction of, and venue in, the state and federal courts in Dallas
County in the State of Texas, in connection with any matter based upon or arising out of this Agreement or the matters contemplated
herein, and agrees that process may be served upon them in any manner authorized by the laws of the State of Texas for such persons.
The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

 

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF,
the undersigned has executed this Warrant to be effective as of the date first written above.

 

	 	DOUGHERTY’S PHARMACY, INC.
	 	 
	 	By:___________________
	 	Name: Stewart Edington
	 	Title: Chief Executive Officer

 

 

 

 

[WARRANT]

 

 

 

 

 

 

 

 

 

 

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]